Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Ascletis Pharma, Inc. ( (HK:1672) ).
Ascletis Pharma reported a modest 5.2% increase in total income to RMB127.4 million for 2025 but saw its net loss widen by 19.6% to RMB359.9 million, driven mainly by a 35.3% surge in research and development spending to RMB409.1 million, while administrative and other expenses declined. The company highlighted substantial progress across its metabolic and immune disease pipelines, including multiple obesity-focused GLP-1, amylin receptor, and multi-agonist candidates advancing toward U.S. IND filings in 2026, positioning Ascletis to participate more aggressively in the fast-growing global obesity and diabetes drug markets despite near-term financial losses.
Ascletis’ lead program ASC30, an oral once-daily GLP-1 tablet, showed encouraging placebo-adjusted weight loss and favorable gastrointestinal tolerability in obesity, with Phase III trials slated for the third quarter of 2026 and an ongoing U.S. Phase II study in diabetes targeting topline data in the same period. The company also advanced a broad next-generation obesity portfolio, including long-acting subcutaneous depot formulations of ASC30, a THRβ-based muscle-preserving weight loss agent ASC47, several amylin receptor and GLP-1R/GIPR dual and triple agonist candidates (ASC35, ASC36, ASC37) and their fixed-dose combinations, with multiple IND submissions to the FDA planned between the second and third quarters of 2026, signaling an aggressive push to build a differentiated, multi-modal obesity franchise.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a Cayman Islands-incorporated biopharmaceutical company focused on developing innovative treatments for metabolic and immune diseases, with a growing emphasis on obesity and related metabolic disorders. Its pipeline includes oral and injectable small-molecule and peptide drug candidates targeting GLP-1, amylin receptors, THRβ, and multi-agonist pathways, with a clear strategy to compete in the global obesity and diabetes therapeutics market.
Average Trading Volume: 2,773,954
Technical Sentiment Signal: Buy
Current Market Cap: HK$17.86B
For detailed information about 1672 stock, go to TipRanks’ Stock Analysis page.